Valeant And Pershing May Sweeten Allergan Deal By $15 A ShareMani
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and Bill Ackman’s Pershing Square are said to be planning to boost their offer to acquire Botox maker Allergan, Inc. (NYSE:AGN) by $15 a share, according to people familiar with the developments.
The enhanced offer marks Valeant and Pershing Square’s third increase to their original bid.
Valeant - Allergan merger could be the largest deal of the year
The latest bid from Valeant Pharmaceuticals and Pershing is intended to keep the Botox maker . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible